pharma · Congenital Adrenal Hyperplasia · Polycystic Ovary Syndrome · SPRB
SPRUCE BIOSCIENCES
SPRUCE BIOSCIENCES, INC.
SPRUCE BIOSCIENCES patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- South San Francisco, USA
- Founded
- 2016
- Employees
- 27
- Programs
- 5
- Drugs
- 3
- Patents
- 9
SPRUCE BIOSCIENCES patents
9 pharmaceutical patents indexed for SPRUCE BIOSCIENCES. 0 expire within 24 months.
SPRUCE BIOSCIENCES has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12115166
Corticotropin releasing factor receptor antagonists
granted -
US 12098152
Methods and compositions for treating polycystic ovary syndrome
granted -
US 11858932
Methods and compositions for treating polycystic ovary syndrome
granted -
US 11351177
Corticotropin releasing factor receptor antagonists
granted -
US 11344557
Corticotropin releasing factor receptor antagonists
granted -
US 11311549
Corticotropin releasing factor receptor antagonists
granted -
US 11304950
Methods for treating testicular and ovarian adrenal rest tumors
granted -
US 11007201
Corticotropin releasing factor receptor antagonists
granted -
US 10849908
Corticotropin releasing factor receptor antagonists
granted
Frequently asked questions
How many patents does SPRUCE BIOSCIENCES have?
9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do SPRUCE BIOSCIENCES patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.